Clinical Trials Results
Results for the search you initiated will be displayed below.
Trial Name
Brief Summary
This phase II/III trial tests whether it is possible to decrease the chance of high-grade
B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual
combination of drugs used for treatment. Venetoclax may stop the growth of cancer cells by
blocking a protein called Bcl-2. Drugs used in usual chemotherapy, such as rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide, work in different ways
to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving venetoclax together with usual
chemotherapy may work better than usual chemotherapy alone in treating patients with
high-grade B-cell lymphomas, and may increase the chance of cancer going into remission and
not returning.
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when
given together with brentuximab vedotin, and how well they work in treating patients with
Hodgkin lymphoma that has returned after a period of improvement or has not responded to
previous treatment. Immunotherapy with monoclonal antibodies, such as ipilimumab and
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of cancer cells to grow and spread. Brentuximab vedotin is a combining monoclonal
antibody with an anticancer drug that binds to a protein on the surface of lymphoma cells
called cluster of differentiation (CD)30 and may kill the cells. It is not known whether
giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer
cells.
This randomized phase III trial studies how well crizotinib works in treating patients with
stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation
in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make
it very active and important for tumor cell growth and progression. Crizotinib may stop the
growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an
effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
This randomized phase II trial studies how well obinutuzumab with or without umbralisib,
lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa
follicular lymphoma that has come back or does not respond to treatment. Immunotherapy with
obinutuzumab, may induce changes in body's immune system and may interfere with the ability
of tumor cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use
substances made from living organisms that may stimulate or suppress the immune system in
different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as
cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and
bendamustine, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving obinutuzumab with or without umbralisib, lenalidomide, or combination
chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.
This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab
vedotin) when given with combination chemotherapy in treating patients with newly diagnosed
stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody,
brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in
a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as
doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. The addition of nivolumab or brentuximab vedotin to combination
chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.
Clinical Trial Categories:
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cancer Control
- Companion Studies
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecology (GYN) Cancer
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Other Cancer Protocols
- Pancreas Cancer
- Sarcoma
- Skin Cancer
- Symptom Management